Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 10/20 | 0.36 |
| ▸ | CASP7 | P55210 | 9/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060012 | 1.00 | CASP3 (0.36) | CASP3CASP7FKBP1AGAACASP1 | |
| SCHEMBL3929383 | 0.91 | FKBP1A (0.37) | CASP3CASP7FKBP1AGAACASP1 | |
| SCHEMBL4314282 | 0.91 | FKBP1A (0.35) | CASP3CASP7FKBP1AGAACASP1 | |
| SCHEMBL3942325 | 0.91 | FKBP1A (0.35) | CASP3CASP7FKBP1AGAACASP1 | |
| SCHEMBL3940425 | 0.89 | FKBP1A (0.34) | CASP3CASP7FKBP1AGAA | |
| SCHEMBL3932125 | 0.86 | FKBP1A (0.37) | CASP3CASP7FKBP1AGAACASP1 | |
| SCHEMBL3942855 | 0.85 | GAA (0.36) | CASP3CASP7FKBP1AGAAALDH1A1 | |
| SCHEMBL4050149 | 0.81 | CNR2 (0.36) | FKBP1AGAAALDH1A1LMNAKMT2A | |
| SCHEMBL3935732 | 0.75 | CASP3 (0.39) | CASP3CASP7GAAKMT2A | |
| SCHEMBL3935727 | 0.75 | CASP3 (0.39) | CASP3CASP7GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | CASP3 4629/4885CASP7 4322/4885FKBP1A 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.